CVS Health to Restore Coverage of Eli Lilly’s Zepbound and Add Foundayo Obesity Pill to Drug Plans
CVS Health's decision to restore coverage for Eli Lilly's Zepbound and add its new obesity pill Foundayo is significant as it enhances patient access to weight loss treatments and strengthens Lilly's competitive position against Novo Nordisk in the market.